Evidence map›Paper›PMID 39024560›Full record

ArticleCancer research2024

Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia.

Constanze Schneider, Hermes Spaink, Gabriela Alexe, Neekesh V Dharia, Ashleigh Meyer, Lucy A Merickel, Delan Khalid, Sebastian Scheich, Björn Häupl, Louis M Staudt and 2 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Constanze SchneiderDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0009-0005-0092-5999
Hermes SpainkDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-2084-9621
Gabriela AlexeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-5668-6297
Neekesh V DhariaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-5048-067X
Ashleigh MeyerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-2851-8915
Lucy A MerickelDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0009-0008-8858-2776
Delan KhalidDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-5044-0336
Sebastian ScheichLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-6408-3536
Björn HäuplGoethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.ORCID 0009-0000-9445-9565
Louis M StaudtLymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-1735-2892
Thomas OellerichGoethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.ORCID 0000-0001-6570-6125
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-0218-7895

Funding

Targeting Pediatric Cancer VulnerabilitiesR35CA283977 · NCI · DANA-FARBER CANCER INST · PI Kimberly Stegmaier · 2023 to 2026
$4.2M
Deutsche Forschungsgemeinschaft (DFG) SCHE 2120/1-1Deutsche Forschungsgemeinschaft (DFG) SCHN 1622/1-1Helen Gurley Brown FoundationNCI NIH HHS R35 CA283977Rally Foundation (Rally Foundation, Inc.)St. Baldrick's Foundation (SBF)The Selig Family Fund for Pediatric Cancer Research
6 · The paper itself

Abstract

Tissue-specific differences in the expression of paralog genes, which are not essential in most cell types due to the buffering effect of the partner pair, can make for highly selective gene dependencies. To identify selective paralogous targets for acute myeloid leukemia (AML), we integrated the Cancer Dependency Map with numerous datasets characterizing protein-protein interactions, paralog relationships, and gene expression in cancer models. In this study, we identified ATP1B3 as a context-specific, paralog-related dependency in AML. ATP1B3, the β-subunit of the sodium-potassium pump (Na/K-ATP pump), interacts with the α-subunit ATP1A1 to form an essential complex for maintaining cellular homeostasis and membrane potential in all eukaryotic cells. When ATP1B3's paralog ATP1B1 is poorly expressed, elimination of ATP1B3 leads to the destabilization of the Na/K-ATP pump. ATP1B1 expression is regulated through epigenetic silencing in hematopoietic lineage cells through histone and DNA methylation in the promoter region. Loss of ATP1B3 in AML cells induced cell death in vitro and reduced leukemia burden in vivo, which could be rescued by stabilizing ATP1A1 through overexpression of ATP1B1. Thus, ATP1B3 is a potential therapeutic target for AML and other hematologic malignancies with low expression of ATP1B1. Significance: ATP1B3 is a lethal selective paralog dependency in acute myeloid leukemia that can be eliminated to destabilize the sodium-potassium pump, inducing cell death.

Indexed as

Leukemia, Myeloid, AcuteSodium-Potassium-Exchanging ATPaseAnimalsCell Line, TumorDNA MethylationHumansMiceATP1A1 protein, humanATP1B1 protein, humanSodium-Potassium-Exchanging ATPase

Identifiers

PMID39024560
PMCPMC11479832

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.